{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:29:16Z","timestamp":1787905756401,"version":"build-2784847793"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.urolonc.2023.08.013","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T16:05:41Z","timestamp":1696521941000},"page":"20.e9-20.e15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sequential endoluminal gemcitabine and docetaxel for the treatment of clinically non-invasive high-grade upper tract urothelial carcinoma"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9991-4301","authenticated-orcid":false,"given":"Ian M.","family":"McElree","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Belzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Mott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vignesh T.","family":"Packiam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan L.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2023.08.013_bib0001","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2023.08.013_bib0002","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","article-title":"European association of urology guidelines on upper urinary tract urothelial carcinoma: 2020 update","volume":"79","author":"Roupr\u00eat","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.08.013_bib0003","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/JU.0000000000003480","article-title":"Diagnosis and management of non-metastatic upper tract urothelial carcinoma: AUA\/SUO guideline","volume":"209","author":"Coleman","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2023.08.013_bib0004","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.eururo.2016.07.014","article-title":"Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU non-muscle invasive bladder cancer guidelines panel","volume":"70","author":"Seisen","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.08.013_bib0005","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.21037\/tau.2019.11.09","article-title":"Future strategies to enhance kidney preservation in upper urinary tract urothelial carcinoma","volume":"9","author":"Metcalf","year":"2020","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.urolonc.2023.08.013_bib0006","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.eururo.2011.07.051","article-title":"Antegrade perfusion with bacillus Calmette-Gu\u00e9rin in patients with non\u2013muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit?","volume":"60","author":"Giannarini","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.08.013_bib0007","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1089\/end.2016.0871","article-title":"Induction and maintenance adjuvant mitomycin C topical therapy for upper tract urothelial carcinoma: tolerability and intermediate term outcomes","volume":"31","author":"Metcalfe","year":"2017","journal-title":"J Endourol"},{"key":"10.1016\/j.urolonc.2023.08.013_bib0008","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3233\/BLC-179018","article-title":"Messing EM: The BCG Shortage","volume":"3","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urolonc.2023.08.013_bib0009","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline","volume":"198","author":"Chang","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2023.08.013_bib0010","doi-asserted-by":"crossref","unstructured":"Steinberg RL, Thomas LJ, O'Donnell MA, et al: Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer. Bladder Cancer 1: 65\u201372.","DOI":"10.3233\/BLC-150008"},{"key":"10.1016\/j.urolonc.2023.08.013_bib0011","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2023.08.013_bib0012","article-title":"Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer","author":"Chevuru","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2023.08.013_bib0013","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/JU.0000000000002740","article-title":"Sequential intravesical gemcitabine and docetaxel for BCG-Na\u00efve high-risk non-muscle invasive bladder cancer","volume":"208","author":"McElree","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2023.08.013_bib0014","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0849","article-title":"Comparison of sequential intravesical gemcitabine and docetaxel vs bacillus Calmette-Gu\u00e9rin for the treatment of patients with high-risk non\u2013muscle-invasive bladder cancer","volume":"6","author":"McElree","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urolonc.2023.08.013_bib0015","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/472831","article-title":"Review of topical treatment of upper tract urothelial carcinoma","volume":"2009","author":"Nepple","year":"2009","journal-title":"Adv Urol"},{"key":"10.1016\/j.urolonc.2023.08.013_bib0016","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.urology.2019.10.005","article-title":"Percutaneous image-guided core needle biopsy for upper tract urothelial carcinoma","volume":"135","author":"Joseph","year":"2020","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2023.08.013_bib0017","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/j.juro.2006.07.049","article-title":"Natural history of positive urinary cytology after radical cystectomy","volume":"176","author":"Raj","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2023.08.013_bib0018","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1464-410X.2012.11068.x","article-title":"Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review","volume":"110","author":"Cutress","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2023.08.013_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/OTT.S225301","article-title":"Optimal management of upper tract urothelial carcinoma: current perspectives","volume":"13","author":"Leow","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.urolonc.2023.08.013_bib0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.urology.2008.06.026","article-title":"A 20-year experience with percutaneous resection of upper tract transitional carcinoma: is there an oncologic benefit with adjuvant bacillus Calmette Gu\u00e9rin therapy?","volume":"73","author":"Rastinehad","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2023.08.013_bib0021","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4103\/0974-7796.115746","article-title":"Mitomycin C instillation following ureterorenoscopic laser ablation of upper urinary tract carcinoma","volume":"5","author":"Aboumarzouk","year":"2013","journal-title":"Urol Ann"},{"key":"10.1016\/j.urolonc.2023.08.013_bib0022","unstructured":"U .S. Food & Drug Administration Commissioner O of the: FDA approves first therapy for treatment of low-grade upper tract urothelial cancer. FDA 2020. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-therapy-treatment-low-grade-upper-tract-urothelial-cancer, Accessed March 3, 2023."},{"key":"10.1016\/j.urolonc.2023.08.013_bib0023","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S1470-2045(20)30147-9","article-title":"Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial","volume":"21","author":"Kleinmann","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2023.08.013_bib0024","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/21681805.2017.1295102","article-title":"Diagnostic accuracy of upper tract urothelial carcinoma: how samples are collected matters","volume":"51","author":"Malm","year":"2017","journal-title":"Scand Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143923002892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143923002892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:28:10Z","timestamp":1761042490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143923002892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1078143923002892"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2023.08.013","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sequential endoluminal gemcitabine and docetaxel for the treatment of clinically non-invasive high-grade upper tract urothelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2023.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}